Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report

J Reprod Med. 1999 Sep;44(9):775-8.

Abstract

Objective: To investigate positron emission tomography (PET) with (fluorine-18)-2-deoxyglucose (FDG) for detecting recurrent ovarian carcinoma.

Study design: Wholebody FDG-PET scanning was performed on five patients before surgical exploration. All five patients were suspected of having recurrence based upon clinical findings and underwent surgery after scanning.

Results: In all five patients, PET images demonstrated increased FDG uptake in a distribution that correlated with surgical-pathologic findings (100%); computer tomography can detect 60% of such patients with malignant disease. Two cases with unexplained elevated serum CA-125 had lesions localized by PET.

Conclusion: Recurrence of ovarian carcinoma was clearly imaged with FDG-PET and was confirmed by surgical pathology. FDG-PET might be a fairly effective tool for detecting recurrent ovarian carcinoma.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CA-125 Antigen / blood
  • Deoxyglucose*
  • Female
  • Fluorine Radioisotopes*
  • Humans
  • Magnetic Resonance Imaging
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Neoplasm Recurrence, Local / pathology
  • Ovarian Neoplasms / diagnosis
  • Ovarian Neoplasms / diagnostic imaging*
  • Ovarian Neoplasms / pathology
  • Tomography, Emission-Computed*
  • Tomography, X-Ray Computed

Substances

  • CA-125 Antigen
  • Fluorine Radioisotopes
  • Deoxyglucose